primary

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies…

1 week ago

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular…

4 weeks ago

Silver Lake and Nomura Securities Form a Strategic Partnership to Establish a Primary Trading Account and Co-Create a New Blueprint for Japans Capital Markets

Menlo Park, California, March 06, 2026 (GLOBE NEWSWIRE) -- We are pleased to announce that Silver Lake Partners, a global…

2 months ago

Star Health Launches 32 Arogya Seva Kendras; to Provide Primary Healthcare Access to over a Million Lives

First Arogya Seva Kendra inaugurated in Egmore, Chennai; Tamil Nadu rollout includes Nagercoil, Thoothukudi, Tiruppur and KarurStructured clinics to offer doctor…

2 months ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…

3 months ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

5 months ago

Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock

December 04, 2025 22:05 ET  | Source: Symbotic Inc. WILMINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq:…

5 months ago

Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

5 months ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

November 08, 2025 11:45 ET  | Source: Vor Biopharma Treatment with telitacicept for 39 weeks resulted in a rapid, clinically…

6 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease

October 22, 2025 16:30 ET  | Source: Vor Biopharma CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:…

6 months ago